Chemical activators of Olr175 employ various intracellular signaling pathways to modulate its activity. Forskolin, for instance, directly engages adenylate cyclase to raise the levels of cyclic AMP within cells. This increase in cAMP triggers the activation of protein kinase A (PKA), a kinase that can phosphorylate specific substrates, including Olr175, leading to its activation. Similarly, Dibutyryl-cAMP, a cAMP analog, permeates cells and resists degradation, thereby sustaining PKA activation which subsequently may activate Olr175 through phosphorylation. Another chemical, Phorbol 12-myristate 13-acetate (PMA), functions by activating protein kinase C (PKC), which phosphorylates serine and threonine residues on its targets. If Olr175 is among these targets, PKC would facilitate its activation through phosphorylation.
Furthermore, Ionomycin acts as a calcium ionophore, which increases the intracellular calcium concentration. This rise in calcium levels can activate calmodulin-dependent kinase (CaMK). If Olr175 is a substrate for CaMK, the kinase would phosphorylate and activate Olr175. Thapsigargin operates by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), similarly resulting in elevated cytosolic calcium, which might activate calcium-dependent kinases capable of modifying Olr175. In addition, Sphingosine-1-phosphate engages its G-protein-coupled receptors, possibly leading to the activation of downstream kinases that phosphorylate Olr175. On another front, Okadaic Acid and Calyculin A inhibit protein phosphatases such as PP1 and PP2A, resulting in sustained phosphorylation and consequently, activation of proteins like Olr175. Anisomycin, which activates the MAPK/ERK pathway, could also lead to the activation of Olr175 through phosphorylation by activated kinases within this pathway. Lastly, Bisindolylmaleimide I and Bisindolylmaleimide IX, both PKC inhibitors, may indirectly activate other kinases that, in turn, phosphorylate and activate Olr175. Each of these chemicals, through their unique mechanisms, can contribute to the state of phosphorylation and activation of Olr175.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, raising intracellular calcium concentrations. Increased calcium can activate calmodulin-dependent kinase (CaMK), which may phosphorylate and activate Olr175 if it is a CaMK substrate. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which phosphorylates serine and threonine residues on target proteins. If Olr175 is a PKC substrate, phosphorylation by PKC would lead to its activation. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate binds to its G-protein-coupled receptors, which can lead to the activation of downstream kinases that may phosphorylate and thereby activate Olr175. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels. This can activate calcium-dependent kinases, which could phosphorylate and activate Olr175. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatases 1 and 2A, preventing dephosphorylation of proteins. Persistent phosphorylation due to inhibited phosphatase activity could maintain Olr175 in an activated state. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is primarily a PKC inhibitor, but it can indirectly lead to the activation of other kinases that may phosphorylate and activate Olr175. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin activates the MAPK/ERK pathway, leading to the activation of kinases that may phosphorylate and activate Olr175. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A inhibits protein phosphatases, particularly PP1 and PP2A, leading to increased phosphorylation levels of proteins. If Olr175 is normally regulated by dephosphorylation, inhibition by Calyculin A could result in its activation. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cAMP analog that can diffuse into cells and resist degradation, leading to PKA activation. PKA can phosphorylate and activate Olr175 if it is among its substrates. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Bisindolylmaleimide IX, another PKC inhibitor, could indirectly lead to the activation of alternative kinases that may phosphorylate and activate Olr175. | ||||||